Petros Pharmaceuticals Announces Reverse Stock Split

November 30, 2022 12:45 PM

Common Stock Will Begin Trading on Split-Adjusted Basis on December 1, 2022NEW YORK, NY / ACCESSWIRE / November 30, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq:PTPI), a leading provider of therapeutics for men's health, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:05...

Read more

Black Bird Biotech Hires Sales and Marketing Firm to Boost MiteXstream Biopesticide Sales Within Cannabis Industry

November 30, 2022 11:00 AM

Black Bird Biotech Hires Sales and Marketing Firm to Boost MiteXstream Biopesticide Sales Within Cannabis IndustryFLOWER MOUND, TX / ACCESSWIRE / November 30, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer and distributor of plant-based MiteXstreamTM biopesticide, today announced that it has hired XCPCNL Business Services Corporation (OTC:XCPL), a venture development business that leverages knowledge, skill, and experience to...

Read more

Lexaria’s DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program

November 29, 2022 8:50 AM

KELOWNA, BC / ACCESSWIRE / November 29, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its patented DehydraTECH-CBD™ has demonstrated performance enhancements compared to one of the world's leading anti-seizure medications, Epidiolex®.Animal seizure study program EPIL-A21-1 was designed to determine whether DehydraTECH-CBD could...

Read more

Apollo Endosurgery to be Acquired by Boston Scientific

November 29, 2022 7:00 AM

Boston Scientific to acquire Apollo for $10.00 per share in cashAUSTIN, TX / ACCESSWIRE / November 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a leading minimally invasive medical device company for gastrointestinal and bariatric procedures, announced today it has entered into a definitive merger agreement to be acquired by Boston Scientific Corporation ("Boston Scientific"), a global medical technology...

Read more

RepliCel Provides Corporate Update

November 28, 2022 6:00 AM

Company Focus on Transformational MilestonesVANCOUVER, BC / ACCESSWIRE / November 28, 2022 / RepliCel Life Sciences Inc. (TSXV:RP)(OTC PINK:REPCF) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide the following corporate update.Dear Shareholders and Stakeholders,RepliCel is pleased to announce that Andrew Schutte has accepted the role of President and CEO. Mr....

Read more

Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference

November 23, 2022 8:00 AM

BOSTON, MA / ACCESSWIRE / November 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 12:10 PM ET. A webcast of the company's...

Read more

Invitation to BioInvent’s R&D Day in Stockholm on December 8, 2022

November 23, 2022 7:00 AM

LUND, SE / ACCESSWIRE / November 23, 2022 / BioInvent International (STO:BINV)Lund, Sweden, November 23, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, invites investors, analysts and media to an R&D Day in Stockholm on Thursday December 8, 2022.The program will start at 2:00...

Read more

Bayer and Ginkgo Bioworks Close Deal Creating Agricultural Biologicals Powerhouse

November 22, 2022 8:30 PM

Ginkgo Bioworks becomes a multi-year strategic partner with Bayer to develop biological solutions in areas such as nitrogen optimization, carbon sequestration, and next generation crop protection / Open Innovation Sourcing is expected to accelerate Biologicals R&D pipeline by tapping into the worldwide open innovation ecosystem / Bayer to continue work to optimize Joyn Bio's nitrogen fixation technology, aiming to complement synthetic...

Read more

BrainChip Adds Rochester Institute of Technology to its University AI Accelerator Program

November 22, 2022 5:30 PM

LAGUNA HILLS, CA / ACCESSWIRE / November 22, 2022 / BrainChip Holdings Ltd. (ASX:BRN, OTCQX:BRCHF, ADR:BCHPY), the world's first commercial producer of ultra-low power neuromorphic AI IP, today announced that the Rochester Institute of Technology (RIT) has joined the University AI Accelerator Program to ensure students have the tools and resources needed to encourage development of cutting-edge technologies that will continue to usher in an era...

Read more

Biovica's DiviTum(R) TKa featured in TK IMPACT study at SABCS

November 22, 2022 9:05 AM

UPPSALA, SE / ACCESSWIRE / November 22, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer monitoring, today announces that the unique study design of the TK IMPACT trial, using the DiviTum® TKa blood test, will be presented as a poster at the world's largest breast cancer symposium, SABCS, on December 8.TK IMPACT is an ongoing prospective, single arm trial that assesses the impact of...

Read more

Biovica's DiviTum(R) TKa Results Presented at SABCS

November 22, 2022 9:00 AM

UPPSALA, SE / ACCESSWIRE / November 22, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer monitoring, today announces that results from a study using the DiviTum® TKa blood test will be presented at the world's largest breast cancer symposium, SABCS, on December 8. The results support using DiviTum® TKa to predict the efficacy of CDK4/6 inhibitors in metastatic breast cancer."These...

Read more

NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate

November 22, 2022 8:00 AM

Topic: Benefits of Immunotherapies Versus Conventional Chemotherapy for Patients and Their Support NetworksCLEVELAND, OH / ACCESSWIRE / November 22, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the availability of its latest monthly installment in a series of fireside chat interviews, with additional sessions to be made available as company developments...

Read more

Apollo Endosurgery Completes Transition to European MDR Requirements for the OverStitch Systems, BIB and Orbera 365 intragastric balloons, and OverTube.

November 21, 2022 8:45 AM

OverStitch has new indications for use statement under CE-Mark, including indications for defect closure, stent fixation, endoscopic sleeve gastroplasty and transoral outlet reductionAUSTIN, TX / ACCESSWIRE / November 21, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that it has successfully transitioned its legacy...

Read more

BrainChip Names Former Arm Executive Nandan Nayampally as Chief Marketing Officer

November 20, 2022 5:30 PM

LAGUNA HILLS, CA / ACCESSWIRE / November 20, 2022 / BrainChip Holdings Ltd (ASX:BRN)(OTCQX:BRCHF)(ADR:BCHPY), the world's first commercial producer of neuromorphic AI IP, has hired Nandan Nayampally as Chief Marketing Officer to drive all aspects of marketing, product management and business strategy for the company's AkidaTM event-based AI neural processor IP, and its portfolio of Essential AI enabling technology solutions.Nayampally is an...

Read more

BioInvent Receives FDA IND Approval for Anti-FcyRIIB Antibody BI-1607

November 18, 2022 2:20 AM

LUND, SE / ACCESSWIRE / November 18, 2022 / BioInvent International (STO:BINV)Phase 1/2a trial in combination with trastuzumab is cleared to be extended to U.S. centersBioInvent has four drugs in five clinical trials, underlining productivity of proprietary technology platformLund, Sweden - November 18, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development...

Read more

Positive 3-Year VenoValve(R) First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular Issues

November 17, 2022 12:00 PM

First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 3 years post-surgeryNo venous ulcer recurrences or CVI relapsesStability in improvements for all study endpoints including reflux, disease severity (rVCSS), and pain (VAS)IRVINE, CA / ACCESSWIRE / November 17, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous...

Read more

Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform

November 16, 2022 8:35 AM

Appointment of Dr. Spicer to Scientific Advisory Board bolsters expertise in Neutrophil Extracellular Traps ("NETs") in cancer biology and provides valuable assistance in advancing development of the Company's DNase platformFRAMINGHAM, MA / ACCESSWIRE / November 16, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard...

Read more

Enzolytics, Inc. Announces Expansion of Production of Its Monoclonal Antibody Therapeutics and Marketing of IPF Immune(TM)

November 16, 2022 8:20 AM

COLLEGE STATION, TX / ACCESSWIRE / November 16, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Enzolytics, Inc. is a drug development company committed to the commercialization of its multiple proprietary therapeutics for the treatment of debilitating infectious diseases. The Company's proprietary technologies include therapeutics for treating HIV and monoclonal antibodies for infectious diseases including HIV, SARS-CoV-2, and...

Read more

Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update

November 15, 2022 8:00 AM

NEW YORK, NY / ACCESSWIRE / November 15, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced financial results for the third quarter ended September 30, 2022.Recent Highlights:Company reported results of an Indian study published in the International Journal of Urology , in which patients reported improvement in erectile function compared to...

Read more

Adolore BioTherapeutics Invited to Present at the 16th Annual Pain Therapeutics Summit

November 14, 2022 10:00 AM

Company to discuss its next generation, disease-modifying, non-opioid analgesic gene therapy in development for the treatment of chronic painDELRAY BEACH, FL / ACCESSWIRE / November 14, 2022 / Adolore BioTherapeutics, Inc. ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free pain relieving (analgesic) treatments for chronic pain, today announced that Roy Clifford Levitt, MD, Founder and Executive...

Read more